| First Author | Tsuji F | Year | 1998 |
| Journal | Biochem Pharmacol | Volume | 55 |
| Issue | 3 | Pages | 297-304 |
| PubMed ID | 9484795 | Mgi Jnum | J:44725 |
| Mgi Id | MGI:1101239 | Doi | 10.1016/s0006-2952(97)00464-4 |
| Citation | Tsuji F, et al. (1998) Involvement of leukotriene B4 in murine dermatitis models. Biochem Pharmacol 55(3):297-304 |
| abstractText | Leukotriene B4 (LTB4) is a product of the 5-lipoxygenase pathway of arachidonic acid (AA) metabolism. LTB4 is a potent chemotactic factor for neutrophils and has been postulated to play an important role in a variety of pathological conditions including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. To investigate the role of LTB4 in dermatitis, we used S-(4-dimethylaminobenzyl)-N-[(2S)-3-mercapto-2-methylpropionyl]-L- cysteine (SA6541), a potent leukotriene A4 (LTA4) hydrolase inhibitor. SA6541 inhibited LTB4 production with an IC50 value of 270 nM in vitro. 5-Hydroperoxyeicosatetraenoic acid (5- HPETE) or AA injection induced LTB4 production and neutrophil influx in mouse ear. SA6541 inhibited 5-HPETE- and AA-induced LTB4 production and neutrophil influx in mouse ear when administered orally at a dose of 50 mg/kg. SA6541 also inhibited 5-HPETE-induced prostaglandin E2 (PGE2) production, probably by an indirect effect through the inhibition of LTB4 production. These results suggest that LTB4 may be important in the pathogenesis of dermatitides such as psoriasis. |
